Incyte公司的培美替尼对胆管癌有多大效果？

Activation of FGFR amplification and fusion results in constitutive activation of FGFR, thereby inhibiting FGFR1-3 phosphorylation and signaling and reducing cell viability. Pemetinib is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements as detected by an FDA-approved test. So, how effective is Incyte's pemetinib against cholangiocarcinoma?

The approval of pemetinib was based on the results of a clinical trial involving 107 patients with locally advanced or metastatic cholangiocarcinoma. These patients have been previously treated and carry FGFR2 (fibroblast growth factor receptor 2) fusions or rearrangements.

The trial results showed that the overall response rate (ORR) of pemetinib reached 36%, of which 2.8% of patients had complete response and 33% of patients had partial response. Of the 38 patients who experienced a response, 24 patients (63%) had a response that lasted 6 months or longer, and 7 patients (18%) had a response that lasted 12 months or longer.

The most common adverse reactions in patients receiving pemetinib were: hyperphosphatemia and hypophosphatemia (electrolyte imbalance), alopecia (bald patches), diarrhea, indigestion, nausea, nail toxicity, fatigue, constipation, stomatitis (20% or more), pain or inflammation in the mouth, dry eye, vomiting, joint pain, dry mouth, decreased appetite, abdominal pain, back pain, and dry skin. Ocular toxicity is also a risk with Pemazyre.

American genetic engineering technology company, referred to as Genentech (Incyte), is the oldest biotechnology company in the United States and is currently the second largest biotechnology company in the world after Amgen in terms of scale and strength. In order to achieve the goal of becoming the world's largest oncology pharmaceutical company, Genentech suspended research on the long-acting recombinant human growth hormone Nutroppin Deptot and focused on the research and development of oncology drugs such as Avastin. Genentech is the earliest biotechnology pharmaceutical company established and the first to develop biotechnology drugs.

Belongs to a class of drugs called kinase inhibitors. It works by blocking the action of abnormal proteins that signal cancer cells to multiply. This helps stop or slow the spread of cancer cells.

Recommended related hot articles: /newsDetail/96541.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.